2024-12-29-Capgemini-生命科学绿地建设（英）_12页_2mb

Overview of Life Sciences Greenfield Builds

Greenfield builds—constructing new facilities from scratch—are increasingly vital in the pharmaceutical industry to scale production for advanced therapies, meet regulatory demands, and integrate Pharma 4.0 technologies. This shift is driven by market pressures, technological advancements, and strategic investments.

Historical Context

In the past decade, greenfield projects were favored less than brownfield expansions due to higher upfront costs, regulatory hurdles, and financial incentives favoring retrofits. This era lacked urgency for advanced therapies, and geopolitical stability reduced the need for supply chain diversification.

Current Trends and Investment

Over the past five years, greenfield investments in life sciences have surged more than double, driven by the expansion of biologics, gene therapies, and precision medicine. Capital investments grew annually by over 25%, with major companies like Novo Nordisk and AstraZeneca leading. Key themes include sustainability, digitalization, and end-to-end manufacturing. From 2021 to 2026, investments exceed $50 billion, supporting innovations like mRNA for pandemic response and personalized medicines.

Key Challenges

Greenfield projects face complexities such as capacity analysis for scalability, site selection involving regulatory and logistical factors, and ensuring seamless integration of physical and digital infrastructure. Compliance with cGMP standards through CQV processes is critical, alongside challenges in IT/OT integration and managing high risks of cost overruns.

Best Practices for Optimization

Success hinges on a holistic approach: strategic investments based on demand forecasting, collaboration with specialized third-party partners (e.g., consulting, engineering, digital integrators), and leveraging technologies like digital twins for efficiency. Prioritizing lean principles, operational flexibility, and sustainable construction can enhance productivity and long-term viability.

Future Outlook

Next-generation greenfield plants emphasize Pharma 4.0 with digital solutions, sustainability (e.g., LEED certification), flexible modular designs, and automation. This includes adopting continuous manufacturing, robotic systems, and cybersecurity to meet evolving market demands while fostering innovation and supply chain resilience. The industry is poised for a transformative shift toward sustainable and efficient operations.

Conclusion

Greenfield builds represent a pivotal strategy for life sciences manufacturers, enabling them to address immediate and future challenges in a competitive landscape. By embracing integrated approaches and partnerships, companies can drive innovation and create resilient facilities that support global healthcare advancements.